| 111 / Čes. slov. Farm. 2026;75(2):108-111 / ČESKÁ A SLOVENSKÁ FARMACIE www.csfarmacie.cz MEDICAMENTA NOVA Atrasentan: nová molekula v léčbě IgA nefropatie a jiných glomerulopatií LITERATURA 1. Moedt E, Wasehuus VS, Heerspink HJL. Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application. Nephrol Dial Transplant. 2025;40(Supplement_1):i37-i46. doi: 10.1093/ndt/gfae214. 2. Cheung CK, Barratt J. The Rapidly Changing Treatment Landscape of IgA Nephropathy. Semin Nephrol. 2024;44(5):151573. doi: 10.1016/j.semnephrol.2025.151573. 3. Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo- -controlled trial. Lancet. 2019;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. 4. Kohan DE, Pritchett Y, Molitch M, et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol. 2011;22(4):76372. doi: 10.1681/ASN.2010080869. 5. Tian Z, Yang Y, Mei J, et al. Efficacy and safety of endothelin A receptor antagonists in IgA nephropathy: a systematic review and meta-analysis. Clin Kidney J. 2025;18(3):sfaf066. doi: 10.1093/ckj/sfaf066. 6. Keam SJ. Atrasentan: First approval. Drugs 2025; 85:1311-1317. doi: 10.1007/s40265-02502208. 7. Heerspink HJL, Andress DL, Bakris G, et al. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018;20(6):1369-1376. doi: 10.1111/dom.13245. 8. Zonnenberg BA, Groenewegen G, Janus TJ, et al. Phase I dose-escalation study of the safety and pharmacokinetics for refractory prostate cancer. Clin Cancer Res 2003; 8(8):2965-72. 9. PharmaTimes. FDA rejects Abbott's prostate cancer drug Xinlay [Internet]. PharmaTimes; 2005 [cited 2026 May 20]. Available from: https://pharmatimes.com/news/fda_rejects_abbotts_prostate_cancer_drug_xinlay_998863/. 10. Trials and Tribulations in Prostate Cancer Xinlay Rejected by US FDA Committee. Pharmaceutical & Diagnostic Innovatio. 2005;3(10):11-13. 11. Waijer SW, Gansevoort RT, Bakris GL, et al. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial. Clin J Am Soc Nephrol. 2021;16(12):1824-1832. doi: 10.2215/CJN.07340521. 12. Heerspink HJL, Kohan DE, de Zeeuw D. New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction. Kidney Int. 2021;99(2):346-349. doi: 10.1016/j.kint.2020.09.026. 13. Gholizadeh Ghozloujeh Z, Selvaskandan H, Wiegley N, et al. IgA Nephropathy: An Overview of the Clinical Trials. Kidney Med. 2025;7(10):101078. doi: 10.1016/j. xkme.2025.101078. 14. Heerspink HJL, Jardine M, Kohan DE, et al. Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy. Kidney Int Rep. 2024;10(1):217-226. doi: 10.1016/j.ekir.2024.10.004. 15. Mottl AK, Mastroianni-Kirsztajn G, Noronha IL, et al. Baseline Characteristics of ASSIST: Phase 2 Crossover Trial of Atrasentan in Adults with IgAN on SGLT2 Inhibitors. J Am Soc Nephrol. 2025;36(10S):10.1681/ASN.20251m9dyn78. 16. Heerspink HL, Barratt J, Gorriz Teruel JL, et al. Assist study design: A randomized, double- -blind, placebo-controlled, crossover study of atrasentan in patients with IgA nephropathy (IgAN) on SGLT2i. Nephrol Dial Transplant 2023; Volume 38, Issue Supplement_1, doi.org/10.1093/ndt/gfad063c_4341. 17. Kim SG, Inker LA, Packham DK, et al. WCN23-1126 Atrasentan for the treatment of IgA nephropathy: Interim results of the AFFINITY study. Kidney Int Rep. 2023; 8(9):1902. doi. org/10.1016/j.ekir.2023.02.1088. 18. Barratt J, Kim SG, Inker LA, et al. AFFINITY Study: 1-Year Results of Atrasentan in IgA Nephropathy. J Am Soc Nephrol 2024;35(10S):10.1681/ASN.2024sd7jz4q0. doi: 10.1681/ ASN.2024sd7jz4q0. 19. Barrat J, VO ND, Lee S, et al. AFFINITY study: 1y results of atrasentan in IgAN patients with UPCR < 1 and ≥1g/g. Abstract #G-447. Am J Kid Dis. 2025; S140-S141. doi: 10.1053/j. ajkd.2025.02.0448. AI-dialogy: NESTÍHÁTE ČÍST? POSLOUCHEJTE. Pro lékaře, kteří chtějí mít přehled a šetřit čas Recenzované články napříč obory v audio formě Naskenujte QR kód, vyberte téma a poslouchejte
RkJQdWJsaXNoZXIy NDA4Mjc=